Palbociclib (PD-0332991) is extensively evaluated across numerous clinical trials spanning Early Phase 1 through Phase 4 investigations. Clinical research predominantly targets estrogen receptor-positive and HER2-negative metastatic breast cancer, while also encompassing advanced clear cell renal cell carcinoma, sarcoma, and KRAS-mutant non-small cell lung cancer. Sponsored by industry leaders such as Pfizer alongside institutional sponsors including the National Cancer Institute, Dana-Farber Cancer Institute, and M.D. Anderson Cancer Center, these studies span completed, active, recruiting, and upcoming trials evaluating novel combination regimens.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05725200 | RECRUITING | Metastatic Colorectal Cancer |
Oslo University Hospital |
2022-09-27 | PHASE2 |
| NCT03424005 | RECRUITING | Metastatic Breast Cancer |
Hoffmann-La Roche |
2018-03-30 | PHASE1; PHASE2 |
| NCT07683754 | NOT_YET_RECRUITING | Advanced Breast Cancer; Metastatic Breast Cancer; HER2 Positive; HR Positive |
Daiichi Sankyo |
2026-09-04 | PHASE3 |
| NCT05564377 | RECRUITING | Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm |
National Cancer Institute (NCI) |
2023-04-07 | PHASE2 |
| NCT05768139 | RECRUITING | Breast Cancer; Solid Tumors, Adult |
Eli Lilly and Company |
2023-04-17 | PHASE1; PHASE2 |
| NCT06380751 | RECRUITING | Advanced Breast Cancer |
AstraZeneca |
2024-08-01 | PHASE3 |
| NCT04606446 | RECRUITING | Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer |
Pfizer |
2020-11-16 | PHASE2 |
| NCT07061717 | NOT_YET_RECRUITING | Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2025-07-01 | PHASE3 |
| NCT07748208 | NOT_YET_RECRUITING | Breast Cancer; Diabetes Type II |
Hoffmann-La Roche |
2026-09-01 | PHASE2 |
| NCT04802759 | RECRUITING | Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer |
Hoffmann-La Roche |
2021-06-22 | PHASE1; PHASE2 |
| NCT07174336 | RECRUITING | Breast Neoplasms; Neoplasm Metastasis |
Eli Lilly and Company |
2025-12-22 | PHASE3 |
| NCT07492641 | RECRUITING | HR+/HER2- Breast Cancer |
BeOne Medicines |
2026-05-22 | PHASE3 |
| NCT06757634 | RECRUITING | Breast Cancer |
Celcuity Inc |
2025-07-24 | PHASE3 |
| NCT07787520 | NOT_YET_RECRUITING | Patients With Advanced Solid Tumors |
Laekna Limited |
2026-08 | PHASE1 |
| NCT06760637 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Pfizer |
2025-01-06 | PHASE3 |
| NCT06997029 | RECRUITING | Advanced Solid Tumor; Advanced Breast Cancer; Advanced Ovarian Cancer |
Bristol-Myers Squibb |
2025-08-01 | PHASE1 |
| NCT02896335 | RECRUITING | Metastatic Malignant Neoplasm to Brain; Recurrent Brain Metastases; Progressive Brain Metastases |
Massachusetts General Hospital |
2017-02-02 | PHASE2 |
| NCT06377852 | RECRUITING | Metastatic Breast Cancer |
American Society of Clinical Oncology |
2024-10-29 | PHASE3 |
| NCT05554367 | ACTIVE_NOT_RECRUITING | Exocrine Pancreas Carcinoma; Malignant Solid Neoplasm; Ovarian Low Grade Serous Adenocarcinoma; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8 |
National Cancer Institute (NCI) |
2023-12-13 | PHASE2 |
| NCT06843967 | RECRUITING | Well Differentiated Liposarcoma; Dedifferentiated Liposarcoma; Liposarcoma; Myxoid Liposarcoma; Round Cell Liposarcoma; Myxoid Pleomorphic Liposarcoma; Pleomorphic Liposarcoma; Unresectable Liposarcoma; Unresectable Dedifferentiated Liposarcoma |
Memorial Sloan Kettering Cancer Center |
2025-02-19 | PHASE1; PHASE2 |
| NCT06062498 | RECRUITING | Estrogen-receptor-positive Breast Cancer; HER2/Neu-Negative Breast Cancer; Advanced Breast Cancerv; Metastatic Breast Cancer |
Northwestern University |
2023-09-29 | PHASE2 |
| NCT06113809 | RECRUITING | Sarcoma |
John Rieth |
2024-02-01 | PHASE1 |
| NCT02942355 | ACTIVE_NOT_RECRUITING | Female Breast Carcinoma; Breast Cancer |
Wake Forest University Health Sciences |
2016-12-07 | PHASE2 |
| NCT07002177 | RECRUITING | Metastatic Breast Cancer; Breast Cancer Stage I; Breast Cancer Stage II; Locally Advanced Breast Cancer (LABC); ER+ Breast Cancer |
Forward Pharmaceuticals Co., Ltd. |
2025-06-01 | PHASE1; PHASE2 |
| NCT04931342 | ACTIVE_NOT_RECRUITING | Ovarian Cancer |
Hoffmann-La Roche |
2021-10-07 | PHASE2 |
| NCT04966481 | RECRUITING | HPV-unrelated Head and Neck Squamous Cell Carcinoma |
Washington University School of Medicine |
2022-04-06 | PHASE3 |
| NCT03454035 | RECRUITING | Tumor, Solid; Pancreatic Cancer; Melanoma |
UNC Lineberger Comprehensive Cancer Center |
2018-01-30 | PHASE1 |
| NCT05867251 | RECRUITING | Advanced Solid Tumor; HR+/HER2- Breast Cancer; HR+, HER2-, Advanced Breast Cancer; CCNE1 Amplification; Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Endometrial Cancer; TNBC - Triple-Negative Breast Cancer |
Avenzo Therapeutics, Inc. |
2023-08-30 | PHASE1; PHASE2 |
| NCT05627232 | RECRUITING | Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia |
Thomas Jefferson University |
2023-08-28 | PHASE1 |
| NCT06692491 | NOT_YET_RECRUITING | Rare Tumour |
Peking University Shenzhen Hospital |
2025-01-01 | PHASE2 |
| NCT04567420 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Criterium, Inc. |
2021-02-09 | PHASE2 |
| NCT03132454 | ACTIVE_NOT_RECRUITING | Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2017-07-25 | PHASE1 |
| NCT04693468 | RECRUITING | Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Recurrent Malignant Solid Neoplasm |
M.D. Anderson Cancer Center |
2020-12-01 | PHASE1 |
| NCT05683418 | RECRUITING | HR+/HER2-negative Breast Cancer |
Totus Medicines |
2023-02-15 | PHASE1 |
| NCT07191977 | NOT_YET_RECRUITING | Esophageal Squamour Cell Cancer |
West China Hospital |
2026-01 | PHASE2 |
| NCT07299890 | NOT_YET_RECRUITING | Breast Cancer |
Anhui Provincial Cancer Hospital |
2025-12-20 | PHASE2 |
| NCT04862663 | ACTIVE_NOT_RECRUITING | Locally Advanced (Inoperable) or Metastatic Breast Cancer |
AstraZeneca |
2021-05-10 | PHASE3 |
| NCT04563507 | RECRUITING | Breast Cancer |
Weill Medical College of Cornell University |
2020-11-12 | PHASE2 |
| NCT07123090 | RECRUITING | Metastatic Renal Cell Carcinoma; Metastatic Renal Cancer; Renal Cell Carcinoma; Advanced Clear Cell Renal Cell Carcinoma; Kidney Cancer; Translocation Renal Cell Carcinoma |
Stephanie Berg |
2025-11-24 | PHASE2 |
| NCT06941142 | NOT_YET_RECRUITING | Advanced Breast Cancer |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2025-04-30 | PHASE1 |
| NCT04985266 | RECRUITING | ER+ Breast Cancer; HER2-negative Breast Cancer |
Royal Marsden NHS Foundation Trust |
2022-03-30 | PHASE2 |
| NCT02925234 | RECRUITING | Cancer; Tumors; Neoplasm; Neoplasia |
The Netherlands Cancer Institute |
2016-08 | PHASE2 |
| NCT06753747 | RECRUITING | Esophagus Cancer |
West China Hospital |
2025-09-10 | PHASE1; PHASE2 |
| NCT06188520 | RECRUITING | ER+ HER2- Advanced Breast Cancer; High-grade Serous Ovarian Cancer (HGSOC) |
AstraZeneca |
2023-12-05 | PHASE1; PHASE2 |
| NCT04360941 | ACTIVE_NOT_RECRUITING | Triple Negative Breast Cancer; Locally Advanced Breast Cancer; Recurrent Breast Cancer; Metastatic Breast Cancer; ER+ Breast Cancer; HER2-positive Breast Cancer |
Royal Marsden NHS Foundation Trust |
2020-08-11 | PHASE1 |
| NCT03304080 | ACTIVE_NOT_RECRUITING | Breast Neoplasms; Breast Diseases |
Icahn School of Medicine at Mount Sinai |
2017-12-20 | PHASE1; PHASE2 |
| NCT03332797 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Genentech, Inc. |
2017-11-24 | PHASE1 |
| NCT05238922 | ACTIVE_NOT_RECRUITING | Solid Tumors |
Incyte Corporation |
2022-07-05 | PHASE1 |
| NCT05432518 | RECRUITING | Glioblastoma; Recurrent Disease; Recurrent Glioblastoma |
AHS Cancer Control Alberta |
2023-06-27 | EARLY_PHASE1 |
| NCT04841148 | RECRUITING | Breast Cancer |
Abramson Cancer Center at Penn Medicine |
2021-06-01 | PHASE2 |
| NCT05665361 | RECRUITING | Advanced Clear Cell Renal Carcinoma (Ccrcc); Papillary Renal Cell Carcinoma (Prcc) |
National Cancer Institute (NCI) |
2024-04-24 | PHASE1; PHASE2 |
| NCT04920708 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer; ER+ Breast Cancer; Advanced Breast Cancer |
Royal Marsden NHS Foundation Trust |
2022-12-28 | PHASE2 |
| NCT05694871 | ACTIVE_NOT_RECRUITING | Advanced Dedifferentiated Liposarcoma; Locally Advanced Dedifferentiated Liposarcoma; Metastatic Dedifferentiated Liposarcoma; Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8; Unresectable Dedifferentiated Liposarcoma |
Alliance for Clinical Trials in Oncology |
2023-06-07 | PHASE2 |
| NCT05216432 | RECRUITING | PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid Tumor |
Relay Therapeutics, Inc. |
2021-12-08 | PHASE1 |
| NCT06736704 | RECRUITING | Advanced Solid Tumors |
Pikavation Therapeutics, Inc. |
2025-02-20 | PHASE1; PHASE2 |
| NCT06947811 | RECRUITING | EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor |
Sun Yat-sen University |
2025-06-09 | PHASE1; PHASE2 |
| NCT05691400 | WITHDRAWN | CYP3A4*22 |
University of Michigan Rogel Cancer Center |
2024-03 | PHASE4 |
| NCT06126276 | RECRUITING | Malignant Female Reproductive System Neoplasm; Malignant Solid Neoplasm; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm |
National Cancer Institute (NCI) |
2024-05-07 | PHASE2 |
| NCT06065748 | RECRUITING | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer |
Hoffmann-La Roche |
2023-12-11 | PHASE3 |
| NCT06207734 | RECRUITING | Breast Cancer |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
2024-01-17 | PHASE2 |
| NCT03065062 | SUSPENDED | Lung Cancer Squamous Cell; Solid Tumors; Head & Neck Cancer; Pancreatic Cancer |
Dana-Farber Cancer Institute |
2017-02-28 | PHASE1 |
| NCT02465060 | ACTIVE_NOT_RECRUITING | Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Exocrine Pancreas Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Kidney Carcinoma; Liver Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Corpus Neoplasm; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Melanoma; Recurrent Multiple Myeloma; Recurrent Ovarian Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Skin Carcinoma; Recurrent Thyroid Gland Carcinoma; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Multiple Myeloma; Skin Carcinoma; Thyroid Gland Carcinoma |
National Cancer Institute (NCI) |
2015-08-17 | PHASE2 |
| NCT03006172 | ACTIVE_NOT_RECRUITING | Breast Cancer; Solid Tumor |
Genentech, Inc. |
2016-12-13 | PHASE1 |
| NCT03297606 | RECRUITING | Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors |
Canadian Cancer Trials Group |
2018-03-23 | PHASE2 |
| NCT05226871 | ACTIVE_NOT_RECRUITING | Breast Cancer; Head and Neck Cancer |
Pfizer |
2022-07-07 | PHASE2 |
| NCT06739395 | RECRUITING | Solid Tumor; Precision Medicine |
Tianjin Medical University Second Hospital |
2024-11-01 | PHASE2 |
| NCT04553133 | ACTIVE_NOT_RECRUITING | Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer |
Pfizer |
2020-09-16 | PHASE2 |
| NCT05909397 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Pfizer |
2023-08-09 | PHASE3 |
| NCT05563220 | ACTIVE_NOT_RECRUITING | Breast Cancer; Metastatic Breast Cancer |
Stemline Therapeutics, Inc. |
2023-01-24 | PHASE1; PHASE2 |
| NCT04216576 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Memorial Sloan Kettering Cancer Center |
2019-12-27 | |
| NCT04185883 | ACTIVE_NOT_RECRUITING | Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation |
Amgen |
2019-12-17 | PHASE1 |
| NCT02738866 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2016-10-25 | PHASE2 |
| NCT04605562 | NOT_YET_RECRUITING | Nasopharyngeal Carcinoma |
Sun Yat-sen University |
2022-06 | PHASE2 |
| NCT03820830 | ACTIVE_NOT_RECRUITING | Breast Cancer Recurrent |
ETOP IBCSG Partners Foundation |
2019-08-27 | PHASE3 |
| NCT02605486 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer (MBC) |
Memorial Sloan Kettering Cancer Center |
2015-11-11 | PHASE1; PHASE2 |
| NCT05468697 | ACTIVE_NOT_RECRUITING | Renal Cell Carcinoma |
Merck Sharp & Dohme LLC |
2022-08-10 | PHASE1; PHASE2 |
| NCT03573648 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2018-11-13 | PHASE2 |
| NCT03609047 | ACTIVE_NOT_RECRUITING | Breast Cancer Stage II; Breast Cancer Stage III |
European Organisation for Research and Treatment of Cancer - EORTC |
2019-06-14 | PHASE2 |
| NCT05069038 | ACTIVE_NOT_RECRUITING | Breast Cancer |
University of Nebraska |
2022-03-02 | PHASE2 |
| NCT05176288 | WITHDRAWN | Advanced Clear Cell Renal Cell Carcinoma |
Bradley A. McGregor, MD |
2024-05-31 | PHASE2 |
| NCT06959979 | RECRUITING | Medulloblastoma, Childhood |
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
2024-11-25 | EARLY_PHASE1 |
| NCT04711252 | ACTIVE_NOT_RECRUITING | ER-Positive HER2-Negative Breast Cancer |
AstraZeneca |
2021-01-28 | PHASE3 |
| NCT04423185 | RECRUITING | Rare Tumor |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2020-08-15 | PHASE2 |
| NCT05501886 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Celcuity Inc |
2022-12-08 | PHASE3 |
| NCT06364956 | RECRUITING | Bladder Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2024-05-15 | PHASE1; PHASE2 |
| NCT04653740 | ACTIVE_NOT_RECRUITING | Advanced Breast Cancer |
Centre Oscar Lambret |
2020-09-08 | |
| NCT04438824 | ACTIVE_NOT_RECRUITING | Well-differentiated/Dedifferentiated Liposarcoma |
Memorial Sloan Kettering Cancer Center |
2020-06-17 | PHASE2 |
| NCT05238831 | WITHDRAWN | Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8 |
OHSU Knight Cancer Institute |
2023-01-30 | EARLY_PHASE1 |
| NCT06570031 | COMPLETED | Hormone Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer |
Ono Pharmaceutical Co., Ltd. |
2021-11-09 | PHASE1 |
| NCT05969184 | COMPLETED | Breast Neoplasm Female |
Peking University Cancer Hospital & Institute |
2021-12-12 | PHASE2 |
| NCT03065387 | TERMINATED | Advanced Malignant Solid Neoplasm; EGFR Gene Amplification; EGFR Gene Mutation; ERBB2 Gene Amplification; ERBB2 Gene Mutation; ERBB3 Gene Mutation; ERBB4 Gene Mutation; KRAS Gene Mutation; Metastatic Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm |
M.D. Anderson Cancer Center |
2017-10-31 | PHASE1 |
| NCT05207709 | TERMINATED | Metastatic Breast Cancer |
SOLTI Breast Cancer Research Group |
2022-03-28 | PHASE3 |
| NCT05266105 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Olema Pharmaceuticals, Inc. |
2021-12-10 | PHASE1 |
| NCT06757335 | NOT_YET_RECRUITING | Breast Cancer |
Hinova Pharmaceuticals Inc. |
2025-01-07 | PHASE1; PHASE2 |
| NCT04546009 | ACTIVE_NOT_RECRUITING | Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer |
Hoffmann-La Roche |
2020-10-09 | PHASE3 |
| NCT06478927 | RECRUITING | Hepatocellular Carcinoma |
Henan Cancer Hospital |
2024-01-15 | |
| NCT06940349 | RECRUITING | Solid Tumors Refractory to Standard Therapy |
Rabin Medical Center |
2021-10-21 | PHASE1; PHASE2 |
| NCT04220476 | WITHDRAWN | Breast Cancer |
Weill Medical College of Cornell University |
2020-03-04 | PHASE2 |
| NCT04819243 | RECRUITING | Premenopausal HR+/HER2- Metastatic Breast Cancer |
Samsung Medical Center |
2021-08-25 | PHASE2 |
| NCT06810492 | NOT_YET_RECRUITING | Breast Cancer Stage III; Breast Cancer Stage II |
Hongmei Zheng, PhD |
2025-04-01 | |
| NCT03478514 | ACTIVE_NOT_RECRUITING | Mantle Cell Lymphoma; B Cell Lymphoma |
Alliance Foundation Trials, LLC. |
2018-09-11 | PHASE2 |
| NCT06895733 | RECRUITING | Solid Tumor, Adult; Next-generation Sequencing; Precision Medicine |
Tianjin Medical University Second Hospital |
2024-11-27 | PHASE1; PHASE2 |
| NCT06307249 | RECRUITING | Cancer; Solid Tumor; Colorectal Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Targeted Therapy; Chemotherapy; Immunotherapy; Precision Therapy |
Lebanese University |
2023-02-15 | PHASE1 |
| NCT05190094 | RECRUITING | Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer |
International Cancer Research Group, United Arab Emirates |
2022-12-20 | PHASE2 |
| NCT04137640 | UNKNOWN | Breast Cancer |
Shengjing Hospital |
2021-07-19 | PHASE4 |
| NCT02778685 | ACTIVE_NOT_RECRUITING | Metastatic Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7 |
City of Hope Medical Center |
2016-09-30 | PHASE2 |
| NCT06856200 | RECRUITING | Advanced HR - Positive, HER2 - Negative Breast Cancer; Resistant to (Neo)Adjuvant Endocrine Therapy |
Fudan University |
2025-02-28 | |
| NCT04870034 | WITHDRAWN | Colorectal Carcinoma; Lung Adenocarcinoma; Malignant Solid Neoplasm; Pancreatic Carcinoma |
Roswell Park Cancer Institute |
2024-01-15 | EARLY_PHASE1 |
| NCT05766410 | RECRUITING | Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Therapy |
National Taiwan University Hospital |
2022-09-16 | PHASE2 |
| NCT03423199 | UNKNOWN | Breast Neoplasms |
National Cancer Center, Japan |
2018-02-09 | PHASE3 |
| NCT02760030 | COMPLETED | Estrogen Receptor and/or Progesterone Receptor Positive; HER2/Neu Negative; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer |
Ohio State University Comprehensive Cancer Center |
2017-02-16 | PHASE2 |
| NCT05039177 | COMPLETED | Metastatic Colorectal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma |
Erasca, Inc. |
2021-09-20 | PHASE1; PHASE2 |
| NCT03685331 | COMPLETED | Metastatic Breast Cancer; Locally Advanced Breast Cancer; Advanced Breast Cancer; BRCA2 Mutation; BRCA1 Mutation |
Abramson Cancer Center at Penn Medicine |
2020-10-15 | PHASE1 |
| NCT05935748 | TERMINATED | ccRCC; Clear Cell Renal Cell Carcinoma; Kidney Cancer; Kidney Neoplasms; Renal Cancer; Renal Neoplasms; Recurrent Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Refractory Renal Cell Carcinoma; Advanced Renal Cell Carcinoma; Carcinoma; Neoplasms; Carcinoma, Renal Cell; Neoplasms, Glandular and Epithelial; Neoplasm by Histology; Adenocarcinoma; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases |
NiKang Therapeutics, Inc. |
2023-07-28 | PHASE2 |
| NCT04964934 | ACTIVE_NOT_RECRUITING | ER-Positive HER2-Negative Breast Cancer |
AstraZeneca |
2021-06-30 | PHASE3 |
| NCT04498520 | WITHDRAWN | Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Hormone Receptor Positive Breast Carcinoma; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Metastatic Endometrioid Adenocarcinoma; Metastatic Fallopian Tube Carcinoma; Metastatic HER2 Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Ovarian Carcinoma; Metastatic Primary Peritoneal Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Refractory Breast Carcinoma; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Primary Peritoneal Cancer AJCC v8; Stage IV Uterine Corpus Cancer AJCC v8; Stage IVA Fallopian Tube Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Primary Peritoneal Cancer AJCC v8; Stage IVA Uterine Corpus Cancer AJCC v8; Stage IVB Fallopian Tube Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Primary Peritoneal Cancer AJCC v8; Stage IVB Uterine Corpus Cancer AJCC v8 |
Pamela Munster |
2021-03-31 | PHASE1 |
| NCT06654297 | ACTIVE_NOT_RECRUITING | Esophageal Squamous Cell Carcinoma |
West China Hospital |
2024-10-27 | PHASE1 |
| NCT03900884 | ACTIVE_NOT_RECRUITING | Breast Neoplasm Female |
Peter MacCallum Cancer Centre, Australia |
2019-09-25 | PHASE1 |
| NCT03088059 | UNKNOWN | Carcinoma, Squamous Cell of Head and Neck |
European Organisation for Research and Treatment of Cancer - EORTC |
2017-11-16 | PHASE2 |
| NCT05865132 | UNKNOWN | Esophagus Squamous Cell Carcinoma |
AIPING ZHOU |
2023-04-06 | PHASE2 |
| NCT03155620 | ACTIVE_NOT_RECRUITING | Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Histiocytic Sarcoma; Juvenile Xanthogranuloma; Langerhans Cell Histiocytosis; Malignant Glioma; Recurrent Childhood Rhabdomyosarcoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Solid Neoplasm; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Primary Central Nervous System Neoplasm; Recurrent Rhabdoid Tumor; Recurrent Soft Tissue Sarcoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Solid Neoplasm; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Primary Central Nervous System Neoplasm; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Rhabdoid Tumor; Stage III Osteosarcoma AJCC v7; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Osteosarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Stage IVA Osteosarcoma AJCC v7; Stage IVB Osteosarcoma AJCC v7; Wilms Tumor |
National Cancer Institute (NCI) |
2017-07-31 | PHASE2 |
| NCT05759949 | COMPLETED | PIK3CA Mutation; Solid Tumor, Adult; HER2-negative Breast Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Unresectable Solid Tumor; Hormone Receptor Positive Tumor |
Relay Therapeutics, Inc. |
2023-03-29 | PHASE1 |
| NCT05277935 | UNKNOWN | Breast Neoplasm Female; Quality of Life |
Beneficência Portuguesa de São Paulo |
2022-04-22 | |
| NCT05949424 | UNKNOWN | Renal Cell Carcinoma; Ovarian Carcinoma; Thyroid Carcinoma; Breast Carcinoma; Endometrium Carcinoma |
University Medical Center Groningen |
2024-05 | PHASE4 |
| NCT05464173 | UNKNOWN | Breast Cancer |
Biyun Wang, MD |
2022-07-01 | PHASE1; PHASE2 |
| NCT05067530 | NOT_YET_RECRUITING | Triple Negative Breast Neoplasms |
Medical University of Gdansk |
2022-01-01 | PHASE2 |
| NCT05293964 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Jiangsu Simcere Pharmaceutical Co., Ltd. |
2022-05-18 | PHASE1 |
| NCT04720768 | UNKNOWN | Melanoma; Metastasis |
Peter MacCallum Cancer Centre, Australia |
2020-06-04 | PHASE1; PHASE2 |
| NCT04591431 | UNKNOWN | Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer; Other Cancer |
Fondazione per la Medicina Personalizzata |
2020-10-07 | PHASE2 |
| NCT06065592 | UNKNOWN | Cancer; Solid Tumor; Thromboembolism; Cardiovascular Diseases; Immune System Diseases; Inflammatory Diseases; Colon Cancer; Breast Cancer; Prostate Cancer; Hepatocellular Carcinoma; Lung Cancer; Chemotherapy; Immunotherapy |
Lebanese University |
2019-02-01 | PHASE1 |
| NCT03284957 | TERMINATED | Breast Cancer |
Sanofi |
2017-09-20 | PHASE1; PHASE2 |
| NCT02947685 | ACTIVE_NOT_RECRUITING | HER-2 Positive Breast Cancer; Estrogen Receptor Positive Breast Cancer |
Alliance Foundation Trials, LLC. |
2017-06-21 | PHASE3 |
| NCT03242382 | UNKNOWN | Soft-tissue Sarcoma; Osteosarcoma; Chordoma |
Grupo Espanol de Investigacion en Sarcomas |
2017-03-31 | PHASE2 |
| NCT03616587 | ACTIVE_NOT_RECRUITING | ER+ HER2- Advanced Breast Cancer |
AstraZeneca |
2018-10-11 | PHASE1 |
| NCT04072952 | COMPLETED | Breast Cancer |
Arvinas Estrogen Receptor, Inc. |
2019-08-05 | PHASE1; PHASE2 |
| NCT03355157 | COMPLETED | Metastatic Breast Cancer |
GBG Forschungs GmbH |
2018-03-01 | PHASE4 |
| NCT03709680 | ACTIVE_NOT_RECRUITING | Ewing Sarcoma; Solid Tumors; Rhabdoid Tumor; Rhabdomyosarcoma; Neuroblastoma; Medulloblastoma; Diffuse Intrinsic Pontine Glioma |
Pfizer |
2019-05-24 | PHASE2 |
| NCT03870919 | ACTIVE_NOT_RECRUITING | Breast Cancer Stage IV; Radiotherapy; Surgery |
UNICANCER |
2019-10-23 | |
| NCT04946864 | SUSPENDED | Breast Cancer; Solid Tumor, Adult |
Ascentage Pharma Group Inc. |
2021-08-13 | PHASE1; PHASE2 |
| NCT05655598 | WITHDRAWN | Advanced Breast Cancer; Treatment-Refractory Solid Tumors; Retinoblastoma Deficiency; SCLC; Soft Tissue Sarcoma; Endometrial Cancer; Bladder Cancer |
Brown University |
2023-09-12 | PHASE1 |
| NCT05953350 | RECRUITING | Inhibition of Autophagy Synergizes Anti-tumor Effect |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2023-11-07 | PHASE1; PHASE2 |
| NCT04858516 | UNKNOWN | Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer |
Guangdong Provincial People's Hospital |
2021-04-30 | PHASE2 |
| NCT05384119 | TERMINATED | Breast Cancer |
Tvardi Therapeutics, Incorporated |
2023-01-09 | PHASE1 |
| NCT03774472 | COMPLETED | Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2018-08-20 | PHASE1; PHASE2 |
| NCT06331715 | COMPLETED | Bioequivalence |
Megalabs |
2024-02-06 | PHASE4 |
| NCT05665361 | Recruiting | Advanced Clear Cell Renal Carcinoma (Ccrcc)|Papillary Renal Cell Carcinoma (Prcc) |
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
2024-04-24 | Phase 1|Phase 2 |
| NCT03024489 | UNKNOWN | Head and Neck Cancer; Locally Advanced |
Mahidol University |
2017-07-19 | PHASE1; PHASE2 |
| NCT06307457 | Completed | Breast Cancer |
Pfizer |
2024-03-11 | -- |
| NCT05912933 | Not yet recruiting | Breast Cancer |
Pfizer |
2024-03-01 | -- |
| NCT05709158 | Not yet recruiting | Breast Cancer |
Pfizer |
2024-03-01 | -- |
| NCT03844997 | COMPLETED | Acute Myeloid Leukemia; AML |
Sudipto Mukherjee, MD, PhD, MPH |
2019-06-06 | PHASE1; PHASE2 |
| NCT04334330 | UNKNOWN | Breast Cancer; Brain Metastases |
Sun Yat-sen University |
2020-12-04 | PHASE2 |
| NCT04494958 | COMPLETED | Triple Negative Breast Cancer |
Fundacion Oncosur |
2020-11-18 | PHASE1; PHASE2 |
| NCT03535506 | TERMINATED | DCIS |
Georgetown University |
2018-10-08 | PHASE2 |
| NCT03784014 | COMPLETED | Soft Tissue Sarcoma |
Institut National de la Santé Et de la Recherche Médicale, France |
2019-10-19 | PHASE3 |
| NCT02664935 | COMPLETED | Non-Small Cell Lung Cancer; Carcinoma, Squamous Cell; Adenocarcinoma |
University of Birmingham |
2015-05-13 | PHASE2 |
| NCT03854903 | COMPLETED | Metastatic Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Hormone Receptor Positive Breast Cancer |
Georgetown University |
2019-04-01 | PHASE1 |
| NCT05065411 | TERMINATED | Metastatic Breast Cancer |
Veru Inc. |
2022-04-11 | PHASE3 |
| NCT03471663 | COMPLETED | Breast Cancer |
InventisBio Co., Ltd |
2018-03-18 | PHASE1 |
| NCT04996160 | COMPLETED | Acute Lymphoblastic Leukemia, Pediatric; Relapsed Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia |
Tanja Andrea Gruber |
2021-07-09 | PHASE1 |
| NCT05076695 | UNKNOWN | Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer |
Fudan University |
2021-10-15 | PHASE2 |
| NCT02448420 | COMPLETED | Metastatic Breast Cancer |
SOLTI Breast Cancer Research Group |
2015-07 | PHASE2 |
| NCT04191499 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Hoffmann-La Roche |
2020-01-29 | PHASE2; PHASE3 |
| NCT04256941 | TERMINATED | Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2019-05-31 | PHASE2 |
| NCT04818632 | COMPLETED | ER+, HER2-, Metastatic Breast Cancer |
AstraZeneca |
2021-11-12 | PHASE1 |
| NCT04060862 | TERMINATED | Breast Cancer |
Hoffmann-La Roche |
2019-11-21 | PHASE1 |
| NCT04318223 | UNKNOWN | Metastatic Breast Cancer; Locally Advanced Breast Cancer |
Consorzio Oncotech |
2019-07-16 | PHASE2 |
| NCT02668666 | COMPLETED | Hormone Receptor Positive Malignant Neoplasm of Breast; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Estrogen Receptor Positive Breast Cancer; Progesterone Receptor Positive Tumor; Metastatic Breast Cancer |
Oana Danciu, MD |
2017-02-01 | PHASE2 |
| NCT03239015 | UNKNOWN | Rare Tumor; Refractory Tumor |
Baodong Qin |
2017-01-01 | PHASE2 |
| NCT05178888 | COMPLETED | Advanced Solid Tumor |
Mirati Therapeutics Inc. |
2022-01-20 | PHASE1 |
| NCT01356628 | COMPLETED | Advanced Hepatocellular Carcinoma; HCC; Liver Cancer |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2011-05-25 | PHASE2 |
| NCT03446157 | COMPLETED | Cancer of the Colon; Colon Cancer; Colon Neoplasms; Colonic Cancer; Neoplasms, Colonic |
UNC Lineberger Comprehensive Cancer Center |
2018-03-23 | PHASE2 |
| NCT04224272 | COMPLETED | HER2+/HR+ Breast Cancer |
Jazz Pharmaceuticals |
2020-06-10 | PHASE2 |
| NCT04872608 | WITHDRAWN | Metastatic Breast Cancer; Unresectable Breast Cancer |
Memorial Sloan Kettering Cancer Center |
2021-09-09 | PHASE1 |
| NCT04483505 | COMPLETED | Breast Cancer Metastatic; Hormone Receptor Positive Malignant Neoplasm of Breast |
Fundacion CRIS de Investigación para Vencer el Cáncer |
2020-11-25 | PHASE1 |
| NCT03526250 | COMPLETED | Advanced Malignant Solid Neoplasm; Recurrent Childhood Ependymoma; Recurrent Ewing Sarcoma; Recurrent Glioma; Recurrent Hepatoblastoma; Recurrent Kidney Wilms Tumor; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Medulloblastoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Glioma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Medulloblastoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma |
National Cancer Institute (NCI) |
2018-08-13 | PHASE2 |
| NCT04736576 | COMPLETED | Breast Cancer |
Pfizer |
2021-02-24 | |
| NCT03170206 | COMPLETED | Lung Cancer |
Dana-Farber Cancer Institute |
2017-05-31 | PHASE1 |
| NCT03158389 | COMPLETED | Glioblastoma, Adult |
University Hospital Heidelberg |
2018-05-07 | PHASE1; PHASE2 |
| NCT02894398 | COMPLETED | Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast |
iOMEDICO AG |
2016-09-06 | PHASE2 |
| NCT04247633 | UNKNOWN | Breast Cancer |
Samsung Medical Center |
2020-02-11 | PHASE2 |
| NCT04669587 | UNKNOWN | Estrogen Receptor-Positive; HER2-Negative; Locally Advanced Breast Cancer; Metastatic Breast Cancer |
EnhancedBio USA Inc. |
2021-07-26 | PHASE1; PHASE2 |
| NCT05244434 | WITHDRAWN | Advanced Breast Adenocarcinoma; Advanced HER2-Negative Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Hormone Receptor-Positive Breast Carcinoma; Metastatic Breast Adenocarcinoma; Metastatic HER2-Negative Breast Carcinoma; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage IV Breast Cancer AJCC v8 |
City of Hope Medical Center |
2022-07-03 | |
| NCT03054363 | COMPLETED | Breast Cancer |
University of Colorado, Denver |
2017-11-27 | PHASE1; PHASE2 |
| NCT03644186 | COMPLETED | Breast Cancer; Estrogen Receptor Positive Tumor; HER2-positive Breast Cancer |
ETOP IBCSG Partners Foundation |
2019-04-16 | PHASE2 |
| NCT04858997 | UNKNOWN | Breast Neoplasms |
Zhejiang Cancer Hospital |
2021-04-22 | PHASE2 |
| NCT03147287 | ACTIVE_NOT_RECRUITING | Metastatic Breast Cancer |
Dana-Farber Cancer Institute |
2017-09-05 | PHASE2 |
| NCT04801966 | TERMINATED | Cancer |
Peter MacCallum Cancer Centre, Australia |
2021-09-23 | |
| NCT03386929 | TERMINATED | Non-small Cell Lung Cancer Metastatic; Non-small Cell Lung Cancer Stage IIIB |
Worldwide Innovative Network Association |
2017-11-29 | PHASE1; PHASE2 |
| NCT03959891 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Massachusetts General Hospital |
2019-05-30 | PHASE1 |
| NCT03530696 | COMPLETED | HER2-positive Breast Cancer; Breast Cancer; Breast Cancer Stage; Recurrent Breast Cancer; Metastatic Breast Cancer; HER2 Positive Breast Carcinoma |
University of Arizona |
2018-12-06 | PHASE2 |
| NCT03110744 | COMPLETED | Chordoma |
University Hospital Heidelberg |
2017-12-15 | PHASE2 |
| NCT04129151 | TERMINATED | Ewing Sarcoma; Ewing's Sarcoma Recurrent |
Dana-Farber Cancer Institute |
2019-12-05 | PHASE2 |
| NCT03809988 | COMPLETED | Breast Cancer; Advanced Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast |
MedSIR |
2019-04-05 | PHASE2 |
| NCT03691493 | COMPLETED | Anatomic Stage IV Breast Cancer AJCC v8; Estrogen Receptor Positive; HER2/Neu Negative; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Bone; Progesterone Receptor Positive; Prognostic Stage IV Breast Cancer AJCC v8 |
Emory University |
2019-02-08 | PHASE2 |
| NCT05371275 | WITHDRAWN | COVID-19 |
biotx.ai GmbH |
2022-04-21 | PHASE2 |
| NCT03455270 | COMPLETED | Carcinoma, Ductal, Breast; Breast Cancer Female; Breast Neoplasm; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Stage IV Breast Cancer |
G1 Therapeutics, Inc. |
2018-05-09 | PHASE1 |
| NCT02806050 | COMPLETED | Breast Cancer |
University Medical Center Groningen |
2016-09-16 | PHASE2 |
| NCT04288089 | ACTIVE_NOT_RECRUITING | Receptors, Estrogen; Genes, Erbb-2; Breast Neoplasms |
Eisai Inc. |
2020-04-01 | PHASE1 |
| NCT04478266 | TERMINATED | Breast Cancer |
Sanofi |
2020-10-14 | PHASE3 |
| NCT03560856 | UNKNOWN | Breast Cancer; HR+/HER2-negative Breast Cancer; Metastasis |
Assistance Publique - Hôpitaux de Paris |
2018-06-27 | PHASE2 |
| NCT02905318 | ACTIVE_NOT_RECRUITING | Prostate Cancer |
Canadian Cancer Trials Group |
2017-07-04 | PHASE2 |
| NCT03560531 | COMPLETED | Breast Cancer |
Zeno Alpha Inc. |
2018-11-30 | PHASE1; PHASE2 |
| NCT02913430 | COMPLETED | Metastatic Breast Cancer |
Shannon Puhalla |
2018-04-24 | EARLY_PHASE1 |
| NCT03128619 | TERMINATED | Estrogen Receptor Positive; HER2/Neu Negative; Invasive Breast Carcinoma; Multifocal Breast Carcinoma; Postmenopausal; Progesterone Receptor Positive; Stage I Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer |
Jonsson Comprehensive Cancer Center |
2017-08-02 | PHASE1 |
| NCT04856371 | UNKNOWN | Advanced Breast Cancer |
Haihe Biopharma Co., Ltd. |
2021-04 | PHASE1 |
| NCT02626507 | UNKNOWN | Breast Cancer |
Hoffman Oncology |
2016-01 | PHASE1 |
| NCT03389477 | ACTIVE_NOT_RECRUITING | Head and Neck Squamous Cell Carcinoma |
Washington University School of Medicine |
2018-04-27 | PHASE2 |
| NCT02764541 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Dana-Farber Cancer Institute |
2016-05-24 | PHASE2 |
| NCT04130152 | COMPLETED | Breast Cancer |
SOLTI Breast Cancer Research Group |
2019-11-21 | EARLY_PHASE1 |
| NCT02684032 | COMPLETED | Breast Cancer |
Celcuity Inc |
2016-06-14 | PHASE1 |
| NCT03936270 | COMPLETED | Ovarian Cancer |
Latin American Cooperative Oncology Group |
2020-03-05 | PHASE2 |
| NCT06390839 | ACTIVE_NOT_RECRUITING | Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm |
National Cancer Institute (NCI) |
2017-03-22 | PHASE2 |
| NCT03969121 | COMPLETED | Breast Cancer Female; Hormone Receptor Positive Malignant Neoplasm of Breast |
Kyoto Breast Cancer Research Network |
2019-07-16 | PHASE3 |
| NCT03220178 | TERMINATED | Breast Neoplasm |
Palleos Healthcare GmbH |
2017-07-24 | PHASE4 |
| NCT02917005 | UNKNOWN | Metastatic Breast Cancer |
Hamdy A. Azim |
2019-05-07 | PHASE2 |
| NCT02897375 | COMPLETED | Solid Neoplasm; Stage III Pancreatic Cancer; Stage IIIA Breast Cancer; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Breast Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Non-Small Cell Lung Cancer; Stage IVA Pancreatic Cancer; Stage IVB Pancreatic Cancer; Sarcoma; Colorectal Cancer; Head and Neck Cancer; Cancer of Unknown Primary; Bladder Cancer; Ovarian Cancer |
Emory University |
2016-10-24 | PHASE1 |
| NCT04047758 | UNKNOWN | Breast Cancer |
Shengjing Hospital |
2019-09-01 | PHASE3 |
| NCT03965845 | COMPLETED | Solid Tumors; NSCLC; CRC; KRAS Gene Mutation |
Calithera Biosciences, Inc |
2019-06-25 | PHASE1; PHASE2 |
| NCT04585724 | WITHDRAWN | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Prognostic Stage IV Breast Cancer AJCC v8 |
Emory University |
2020-06-12 | PHASE1 |
| NCT03284723 | TERMINATED | Breast Neoplasms |
Pfizer |
2017-11-01 | PHASE1 |
| NCT03981614 | COMPLETED | Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Unresectable Carcinoma |
Academic and Community Cancer Research United |
2019-10-29 | PHASE2 |
| NCT03472573 | COMPLETED | Recurrent B Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2018-05-09 | PHASE1 |
| NCT02603679 | ACTIVE_NOT_RECRUITING | Early-Stage Breast Carcinoma; Estrogen Receptor Positive Tumor |
Thomas Hatschek |
2015-02 | PHASE2 |
| NCT04075604 | COMPLETED | Breast Cancer; Cancer |
Bristol-Myers Squibb |
2019-10-18 | PHASE2 |
| NCT04436744 | COMPLETED | Early Breast Cancer |
Hoffmann-La Roche |
2020-09-04 | PHASE2 |
| NCT03792256 | COMPLETED | Leukemia, Lymphocytic; Lymphoblastic Lymphoma; T-cell Lymphoma; T-cell Leukemia; Recurrent Disease; Acute Leukemia |
Children's Oncology Group |
2019-04-11 | PHASE1 |
| NCT02592746 | UNKNOWN | Metastatic Breast Cancer |
Samsung Medical Center |
2016-06 | PHASE2 |
| NCT01976169 | COMPLETED | Advanced Breast Cancer |
University of Texas Southwestern Medical Center |
2014-01-24 | PHASE1 |
| NCT03322215 | TERMINATED | Breast Cancer Metastatic |
Theodoros Foukakis |
2017-10-24 | PHASE2 |
| NCT03079011 | COMPLETED | Metastatic Breast Cancer |
UNICANCER |
2017-03-22 | PHASE3 |
| NCT03238196 | COMPLETED | Metastatic Breast Cancer |
Vanderbilt-Ingram Cancer Center |
2017-08-18 | PHASE1 |
| NCT01723774 | ACTIVE_NOT_RECRUITING | Breast Neoplasms |
Washington University School of Medicine |
2013-04-10 | PHASE2 |
| NCT03447132 | COMPLETED | Breast Neoplasm Female |
International Cancer Research Group, United Arab Emirates |
2017-12-20 | PHASE3 |
| NCT04439201 | ACTIVE_NOT_RECRUITING | Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Hematopoietic and Lymphoid Cell Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm |
National Cancer Institute (NCI) |
2016-05-31 | PHASE2 |
| NCT02384239 | COMPLETED | Metastatic Breast Cancer; Hormone Receptor Positive |
University of California, San Francisco |
2015-10-19 | PHASE2 |
| NCT02730429 | COMPLETED | Endometrial Cancer |
Nordic Society of Gynaecological Oncology - Clinical Trials Unit |
2017-02-15 | PHASE2 |
| NCT03878524 | TERMINATED | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Castration-Resistant Prostate Carcinoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Locally Advanced Pancreatic Adenocarcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Primary Myelofibrosis; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hematologic Malignancy; Recurrent Hodgkin Lymphoma; Recurrent Myelodysplastic Syndrome; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Recurrent Myeloproliferative Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma; Recurrent Small Lymphocytic Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Chronic Myelomonocytic Leukemia; Refractory Hematologic Malignancy; Refractory Hodgkin Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Myelodysplastic Syndrome; Refractory Myelodysplastic/Myeloproliferative Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Plasma Cell Myeloma; Refractory Primary Myelofibrosis; Refractory Small Lymphocytic Lymphoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma |
OHSU Knight Cancer Institute |
2020-04-01 | PHASE1 |
| NCT02871791 | COMPLETED | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Hormone Receptor (HR)-Positive Breast Cancer |
Dana-Farber Cancer Institute |
2016-08-24 | PHASE1; PHASE2 |
| NCT01522989 | UNKNOWN | Advanced Solid Tumor Malignancies |
Georgetown University |
2011-12 | PHASE1 |
| NCT03628066 | COMPLETED | Breast Cancer |
NSABP Foundation Inc |
2018-10-22 | PHASE2 |
| NCT02513394 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Alliance Foundation Trials, LLC. |
2015-08 | PHASE3 |
| NCT03401359 | UNKNOWN | Breast Cancer Stage IV |
Samsung Medical Center |
2017-10-24 | |
| NCT03184090 | COMPLETED | Metastatic Breast Cancer |
MedSIR |
2017-06-28 | PHASE2 |
| NCT03633331 | COMPLETED | Estrogen Receptor-positive Breast Cancer; HER2/Neu Negative; Stage IV Breast Cancer AJCC v6 and v7 |
Alliance for Clinical Trials in Oncology |
2018-08-15 | PHASE2 |
| NCT02297438 | COMPLETED | Breast Neoplasms |
Pfizer |
2015-03-23 | PHASE3 |
| NCT02536742 | COMPLETED | Metastatic Breast Cancer |
ETOP IBCSG Partners Foundation |
2016-08-30 | PHASE2 |
| NCT02907918 | TERMINATED | Breast Cancer; Cancer of Breast; Breast Carcinoma |
Washington University School of Medicine |
2017-06-30 | PHASE2 |
| NCT01864746 | COMPLETED | Breast Cancer; Hormonreceptor Positive; Her2-normal; Postneoadjuvant Treatment With CDK 4/6 Inhibitor; CPS-EG Score |
GBG Forschungs GmbH |
2013-10-30 | PHASE3 |
| NCT03515200 | TERMINATED | Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission |
St. Jude Children's Research Hospital |
2018-04-20 | PHASE1 |
| NCT02101034 | COMPLETED | Carcinoma, Squamous Cell of Head and Neck |
Washington University School of Medicine |
2014-06-17 | PHASE1; PHASE2 |
| NCT02624973 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Haukeland University Hospital |
2016-04-15 | PHASE2 |
| NCT02349633 | TERMINATED | Non-Small Cell Lung Cancer |
Pfizer |
2015-05-14 | PHASE1; PHASE2 |
| NCT03007979 | COMPLETED | Breast Cancer; Breast Carcinoma; Cancer of Breast; Malignant Tumor of Breast |
Washington University School of Medicine |
2017-06-15 | PHASE2 |
| NCT01823835 | TERMINATED | Breast Cancer |
Genentech, Inc. |
2014-12-29 | PHASE1; PHASE2 |
| NCT03709082 | TERMINATED | HER2-positive Breast Cancer; Breast Cancer Metastatic |
University of Kansas Medical Center |
2018-10-15 | PHASE1; PHASE2 |
| NCT01536743 | COMPLETED | Ovarian Epithelial Carcinoma |
Jonsson Comprehensive Cancer Center |
2011-12-15 | PHASE2 |
| NCT03498378 | ACTIVE_NOT_RECRUITING | Head and Neck Squamous Cell Carcinoma |
Kathryn Gold |
2018-06-06 | PHASE1 |
| NCT03123744 | WITHDRAWN | Cancer, Advanced |
Razelle Kurzrock, MD |
2018-07-01 | PHASE2 |
| NCT02690480 | UNKNOWN | Breast Neoplasms |
Spanish Breast Cancer Research Group |
2016-02-17 | PHASE2 |
| NCT02491983 | COMPLETED | Metastatic Breast Cancer |
MedSIR |
2015-08 | PHASE2 |
| NCT03454919 | UNKNOWN | Melanoma |
Peking University Cancer Hospital & Institute |
2018-03-30 | PHASE2 |
| NCT02692755 | COMPLETED | Hormone Receptor Positive HER-2 Negative Breast Cancer |
Georgetown University |
2016-09 | PHASE2; PHASE3 |
| NCT03756090 | UNKNOWN | Breast Cancer; Breast Diseases; Breast Neoplasms |
Zhejiang Cancer Hospital |
2018-12-01 | |
| NCT02530320 | COMPLETED | Oligodendroglioma; Oligoastrocytoma |
Grupo Español de Investigación en Neurooncología |
2015-10-25 | PHASE2 |
| NCT03219554 | UNKNOWN | Thymic Cancer |
Samsung Medical Center |
2017-08 | PHASE2 |
| NCT01037790 | COMPLETED | Adult Solid Tumor; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Adult Central Nervous System Germ Cell Tumor; Adult Teratoma; Benign Teratoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Familial Testicular Germ Cell Tumor; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Male Breast Cancer; Ovarian Immature Teratoma; Ovarian Mature Teratoma; Ovarian Monodermal and Highly Specialized Teratoma; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Extragonadal Seminoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Melanoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Rectal Cancer; Stage III Extragonadal Non-seminomatous Germ Cell Tumor; Stage III Extragonadal Seminoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Ovarian Germ Cell Tumor; Stage IV Breast Cancer; Stage IV Colon Cancer; Stage IV Extragonadal Non-seminomatous Germ Cell Tumor; Stage IV Extragonadal Seminoma; Stage IV Melanoma; Stage IV Ovarian Germ Cell Tumor; Stage IV Rectal Cancer; Testicular Immature Teratoma; Testicular Mature Teratoma |
Abramson Cancer Center at Penn Medicine |
2009-10 | PHASE2 |
| NCT02530424 | COMPLETED | Breast Neoplasms |
Fondazione Michelangelo |
2015-05 | PHASE2 |
| NCT02448771 | COMPLETED | Breast Cancer Stage IV; Unresectable Locally Advanced Invasive Breast Cancer; Metastatic Invasive Breast Cancer |
Dana-Farber Cancer Institute |
2015-07-09 | PHASE1; PHASE2 |
| NCT03819010 | COMPLETED | Breast Cancer |
MedSIR |
2019-05-07 | PHASE2 |
| NCT02679755 | COMPLETED | Breast Cancer |
Pfizer |
2016-03-09 | PHASE4 |
| NCT02310243 | UNKNOWN | Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia |
University of Ulm |
2015-07 | PHASE1; PHASE2 |
| NCT02600923 | COMPLETED | Advanced Breast Cancer Female |
Pfizer |
2016-04-15 | PHASE3 |
| NCT01320592 | COMPLETED | Breast Cancer |
Abramson Cancer Center at Penn Medicine |
2011-03 | PHASE1 |
| NCT03065621 | COMPLETED | Breast Cancer Female |
Jules Bordet Institute |
2017-07-05 | PHASE2 |
| NCT02255461 | TERMINATED | Childhood Choroid Plexus Tumor; Childhood Ependymoblastoma; Childhood Grade III Meningioma; Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Medulloepithelioma; Recurrent Childhood Anaplastic Astrocytoma; Recurrent Childhood Anaplastic Oligoastrocytoma; Recurrent Childhood Anaplastic Oligodendroglioma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Giant Cell Glioblastoma; Recurrent Childhood Glioblastoma; Recurrent Childhood Gliomatosis Cerebri; Recurrent Childhood Gliosarcoma; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor |
Pediatric Brain Tumor Consortium |
2014-12-08 | PHASE1 |
| NCT02774681 | TERMINATED | Breast Carcinoma Metastatic in the Brain; Estrogen Receptor Negative; HER2/Neu Negative; HER2/Neu Positive; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IV Breast Cancer |
Northwestern University |
2016-08-31 | PHASE2 |
| NCT03194373 | COMPLETED | Squamous Cell Carcinoma of the Head and Neck |
University of Michigan Rogel Cancer Center |
2017-10-12 | PHASE2 |
| NCT02592083 | ACTIVE_NOT_RECRUITING | Early-Stage Breast Carcinoma; Hormone Receptor Positive Tumor |
Thomas Hatschek |
2015-10 | PHASE2 |
| NCT02028507 | COMPLETED | Metastatic Breast Cancer |
Spanish Breast Cancer Research Group |
2014-03-13 | PHASE3 |
| NCT02389842 | COMPLETED | Advanced Solid Tumours; Breast Cancer |
Royal Marsden NHS Foundation Trust |
2015-03-25 | PHASE1 |
| NCT02501902 | COMPLETED | Metastatic Pancreatic Ductal Adenocarcinoma |
Pfizer |
2015-11-23 | PHASE1 |
| NCT02630693 | COMPLETED | Breast Cancer |
Canadian Cancer Trials Group |
2016-04-08 | PHASE2 |
| NCT03377101 | WITHDRAWN | Estrogen Receptor Positive; HER2/Neu Negative; Progesterone Receptor Positive; Stage IV Breast Cancer AJCC v6 and v7 |
National Cancer Institute (NCI) |
2018-08-07 | PHASE2 |
| NCT02499146 | COMPLETED | Advanced Breast Cancer |
Pfizer |
2015-09-11 | PHASE1 |
| NCT02499120 | COMPLETED | Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
Pfizer |
2015-09-10 | PHASE2 |
| NCT02296801 | COMPLETED | Breast Cancer; Breast Carcinoma; Breast Tumors |
NSABP Foundation Inc |
2015-01 | PHASE2 |
| NCT02159755 | ACTIVE_NOT_RECRUITING | Recurrent Mantle Cell Lymphoma |
National Cancer Institute (NCI) |
2014-08-13 | PHASE1 |
| NCT02040857 | COMPLETED | Breast Cancer |
Dana-Farber Cancer Institute |
2014-01 | PHASE2 |
| NCT02599714 | COMPLETED | Advanced and Metastatic Breast Cancer |
AstraZeneca |
2015-12-07 | PHASE1 |
| NCT02400567 | COMPLETED | Neoadjuvant Operable Breast Cancer |
UNICANCER |
2015-01 | PHASE2 |
| NCT02022982 | COMPLETED | KRAS Mutant Non-Small Cell Lung Cancer; Solid Tumors |
Dana-Farber Cancer Institute |
2014-01 | PHASE1 |
| NCT02059213 | COMPLETED | Prostate Cancer |
University of Michigan Rogel Cancer Center |
2014-06 | PHASE2 |
| NCT03220191 | COMPLETED | Healthy Volunteer |
Pfizer |
2017-07-21 | PHASE1 |
| NCT02806648 | COMPLETED | Pancreatic Neuroendocrine Cancer |
Grupo Espanol de Tumores Neuroendocrinos |
2015-05 | PHASE2 |
| NCT02785939 | COMPLETED | CCND1 Gene Amplification; CCND2 Gene Amplification; CCND3 Gene Amplification; CDK4 Gene Amplification; Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7 |
SWOG Cancer Research Network |
2014-09 | PHASE2; PHASE3 |
| NCT02549430 | COMPLETED | Breast Cancer |
Fondazione Sandro Pitigliani |
2012-10 | PHASE2 |
| NCT02334527 | TERMINATED | Metastatic Urothelial Carcinoma (UC) |
UNC Lineberger Comprehensive Cancer Center |
2015-03-17 | PHASE2 |
| NCT01907607 | COMPLETED | Advanced Gastrointestinal Stromal Tumors |
Institut Bergonié |
2014-02 | PHASE2 |
| NCT02202200 | UNKNOWN | Melanoma BRAF V600E/K Mutated; CDNKN2A Loss Defined |
Assistance Publique - Hôpitaux de Paris |
2014-05 | PHASE1; PHASE2 |
| NCT01209598 | COMPLETED | Sarcoma; Liposarcoma |
Memorial Sloan Kettering Cancer Center |
2010-09-23 | PHASE2 |
| NCT02334800 | COMPLETED | Healthy, Hepatic Insufficiency |
Pfizer |
2015-03-31 | PHASE1 |
| NCT02030483 | TERMINATED | Multiple Myeloma |
Weill Medical College of Cornell University |
2014-02 | PHASE1 |
| NCT02065063 | COMPLETED | Cancer |
GlaxoSmithKline |
2014-04-22 | PHASE1 |
| NCT02085538 | COMPLETED | Renal Impairment |
Pfizer |
2014-05 | PHASE1 |
| NCT01684215 | COMPLETED | Neoplasms; Breast Neoplasms |
Pfizer |
2012-10-19 | PHASE2 |
| NCT01740427 | COMPLETED | Breast Neoplasms |
Pfizer |
2013-02-22 | PHASE3 |
| NCT02008734 | COMPLETED | Untreated Operable Early Breast Cancer |
Gustave Roussy, Cancer Campus, Grand Paris |
2014-01 | PHASE2 |
| NCT02311946 | COMPLETED | Healthy |
Pfizer |
2015-01 | PHASE1 |
| NCT01942135 | COMPLETED | Metastatic Breast Cancer |
Pfizer |
2013-09-26 | PHASE3 |
| NCT02222441 | COMPLETED | Healthy |
Pfizer |
2014-10 | PHASE1 |
| NCT02097329 | COMPLETED | Healthy |
Pfizer |
2014-04 | PHASE1 |
| NCT02059330 | COMPLETED | Healthy |
Pfizer |
2014-03 | PHASE1 |
| NCT02131298 | COMPLETED | Healthy |
Pfizer |
2014-05 | PHASE1 |
| NCT02083640 | COMPLETED | Healthy |
Pfizer |
2014-03 | PHASE1 |
| NCT02041273 | COMPLETED | Healthy |
Pfizer |
2014-01 | PHASE1 |
| NCT01291017 | COMPLETED | Non-small Cell Lung Cancer |
University of Florida |
2011-02 | PHASE2 |
| NCT01953731 | COMPLETED | Healthy |
Pfizer |
2013-10 | PHASE1 |
| NCT01906125 | COMPLETED | Healthy |
Pfizer |
2013-09 | PHASE1 |
| NCT01227434 | TERMINATED | Glioblastoma; Gliosarcoma; Anaplastic Astrocytoma |
University of California, San Francisco |
2010-09 | PHASE2 |
| NCT01918176 | COMPLETED | Healthy |
Pfizer |
2013-09 | PHASE1 |
| NCT00721409 | COMPLETED | Breast Cancer |
Pfizer |
2008-09-15 | PHASE2 |
| NCT01904747 | COMPLETED | Healthy |
Pfizer |
2013-07 | PHASE1 |
| NCT01844323 | COMPLETED | Healthy |
Pfizer |
2013-06 | PHASE1 |
| NCT01821066 | COMPLETED | Healthy |
Pfizer |
2013-04 | PHASE1 |
| NCT01756781 | COMPLETED | Healthy |
Pfizer |
2013-05 | PHASE1 |
| NCT01802476 | COMPLETED | Healthy |
Pfizer |
2013-05 | PHASE1 |
| NCT01701375 | TERMINATED | Relapsed Acute Leukemia; Refractory Acute Leukemia; High-Risk Myelodysplasia |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2012-09 | PHASE1 |
| NCT01756768 | COMPLETED | Healthy |
Pfizer |
2013-01 | PHASE1 |
| NCT01111188 | TERMINATED | Mantle Cell Lymphoma |
Weill Medical College of Cornell University |
2010-08-23 | PHASE1 |
| NCT01602887 | COMPLETED | Healthy |
Pfizer |
2012-05 | PHASE1 |
| NCT00555906 | COMPLETED | Multiple Myeloma |
Pfizer |
2008-01 | PHASE2 |
| NCT00420056 | COMPLETED | Lymphoma, Mantle-Cell |
Pfizer |
2007-05 | PHASE1 |
| NCT00141297 | COMPLETED | Neoplasms; Lymphoma, Non-Hodgkin |
Pfizer |
2004-09 | PHASE1 |
| NCT01709370 | UNKNOWN | ER Positive, HER2 Negative Breast Cancer |
Organisation for Oncology and Translational Research |
2012-02 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2023-02-21)
Check the
PD-0332991 (Palbociclib) Hydrochloride
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- PD-0332991 (Palbociclib) Hydrochloride Solubility in DMSO
- PD-0332991 (Palbociclib) Hydrochloride Stock Solution
- PD-0332991 (Palbociclib) Hydrochloride Storage
- PD-0332991 (Palbociclib) Hydrochloride Stability
- PD-0332991 (Palbociclib) Hydrochloride Molecular Weight
- PD-0332991 (Palbociclib) Hydrochloride SMILES
- PD-0332991 (Palbociclib) Hydrochloride CAS Number
- PD-0332991 (Palbociclib) Hydrochloride Chemical Structure (2D and 3D)
- PD-0332991 (Palbociclib) Hydrochloride SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.